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Abstract
Pegylated IFNα (PEG‐IFN) is one of the treatment options for chronic HBV (CHB) 
patients. However, the high patient treatment burden and limited response rate 
together clearly ask for biomarkers to predict PEG‐IFN response. Soluble CD14 
(sCD14) is considered a marker for immune activation and has been shown to pre‐
dict clinical outcome of HIV infection. However, studies on sCD14 in CHB infec‐
tion are inconclusive, and its relationship with clinical outcome is largely unknown. 
Here, we measured sCD14 levels in CHB patients and investigated whether changes 
in sCD14 level related to PEG‐IFN response. Serum sCD14 levels were determined in 
15 healthy controls, 15 acute self‐limited HBV, 60 CHB patients in different disease 
phases and 94 HBeAg+ CHB patients at week 0 and week 12 of a 52‐week PEG‐IFN 
treatment. Response to PEG‐IFN treatment was defined as HBeAg seroconversion 
or HBeAg loss at 26 weeks post‐treatment. The mean sCD14 level in acute HBV 
patients (3.0 µg/mL) was significantly higher than in CHB patients (2.4 µg/mL) and 
healthy controls (2.4 µg/mL). In CHB patients receiving PEG‐IFN, a significant in‐
crease in sCD14 was found after 12‐week treatment (median week 0:2.1 µg/mL; 
week 12:3.7 µg/mL). After 12‐week treatment, the fold change (FC = w12/w0) in 
sCD14 was significantly higher in responders compared to nonresponders (HBeAg 
seroconversion: median FCresponder = 2.1 vs FCnonresponder = 1.6; HBeAg loss: median 
FCresponder = 2.2 vs FCnonresponder = 1.5). Receiver operating characteristic curves dem‐
onstrated that FC‐sCD14wk12/wk0 levels can be of significant value as a stopping rule 
to select patients at week 12 who are not likely to benefit from further PEG‐IFN 
treatment.
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1  | INTRODUC TION
About 1/3 of the world's population has been exposed to hepatitis 
B virus (HBV) during their lifetime, and over 250 million individu‐
als worldwide suffer from chronic HBV (CHB) infection.1 These 
patients are at increased risk of developing liver fibrosis, cirrhosis 
and hepatocellular carcinoma (HCC).2 Currently, there are two main 
treatment options for CHB patients: nucleos(t)ide analogues (NA) 
and pegylated IFNα (PEG‐IFN). NA interfere with viral replication 
but do not eliminate the virus have to be given lifelong and may 
lead to viral escape variants. The other treatment, PEG‐IFN, aims 
to induce long‐term immunological control over the virus after finite 
treatment duration, typically 1 year. PEG‐IFN, however, has a mod‐
erate antiviral effect resulting in a sustained response in only ~25% 
of patients3 and a serious risk of adverse events.4 Considering the 
limited response rate, high costs and severe side effects, indicators 
to predict which individuals are most likely to respond to PEG‐IFN, 
are highly needed. Especially, early on‐treatment predictors are of 
interest to discontinue PEG‐IFN and minimize treatment burden for 
the nonresponding patients.
CD14 is a protein that plays an important role in immunity. 
CD14 acts as a co‐receptor with Toll‐like receptor 4 for the de‐
tection of bacterial lipopolysaccharides (LPS).5 It also recognizes 
other pathogen‐associated molecular patterns such as bacterial li‐
poteichoic acid.6 It exists in two forms, a membrane‐attached form 
(mCD14) and a soluble form (sCD14). mCD14 is a glycosylphospha‐
tidylinositol‐anchored glycoprotein expressed on the surface of 
various cells including myeloid cells7,8 and nonhematopoietic liver 
cells.7 sCD14 is produced by activated monocytes, macrophages 
and primary human hepatocytes.9,10 In serum, it may serve as a bio‐
logical marker for inflammatory disease activity as increased serum 
levels of sCD14 have been detected in patients with bacterial in‐
fections, viral infections,11,12 rheumatic diseases13,14 and multiple 
sclerosis.15
sCD14 has been widely studied as a biomarker in HIV infection 
and liver disease. Elevated sCD14 levels were found in HIV‐infected 
patients compared with seronegative controls,12,16,17 and sCD14 lev‐
els could independently predict disease progression and mortality 
for both HIV‐1 and HIV‐2 infections.16,18,19 In viral hepatitis, high 
levels of baseline plasma sCD14 were associated with worse clini‐
cal outcome in a mixed cohort of CHB and chronic HCV patients.20 
Furthermore, elevated serum sCD14 levels were associated with 
HBV‐related HCC in CHB.21 Finally in HCV, the rise in sCD14 after 
12 weeks of PEG‐IFN treatment was a negative predictor of treat‐
ment response.22 For HBV, however, neither the relation between 
serum sCD14 levels and the natural history of disease nor clinical 
outcome upon PEG‐IFN treatment has been clearly established.
Here, we measured and analysed sCD14 levels in acute HBV in‐
fection, treatment‐naive CHB patients from various disease stages 
and HBeAg+ CHB patients receiving PEG‐IFN. For the latter, we 
characterized the relationship of sCD14 serum levels to PEG‐IFN 
treatment response and assessed the value of sCD14 as an early 
on‐treatment indicator to stop treatment of patients who are un‐
likely to respond.
2  | MATERIAL S AND METHODS
2.1 | Patient selection
Sixty CHB patients who never received treatment attending the out‐
patient hepatology clinic of the ErasmusMC and 15 age‐matched, 
acute self‐limited HBV patients and healthy controls were included 
in our study (Table 1). Serum samples were prospectively collected 
and stored at −80°C. Exclusion criteria for selection in the study are 
described in detail elsewhere.23 A total of 94 HBeAg+ CHB patients, 
who were previously enrolled in an investigator‐initiated multicentre 
randomized trial (99‐01 study) comparing PEG‐IFN monotherapy or 
combination therapy with lamivudine (LAM), were also included.24 
The inclusion and exclusion criteria are similar to the original study.24 
Additional inclusion criteria for the current analysis were completion 
of the 26‐week follow‐up phase of the original study and availability 
of a baseline and 12‐week serum sample for quantification of sCD14 
levels (n = 94). All patients gave written informed consent according 
to the standards of the local ethics committee.
2.2 | Study design
A total of 94 HBeAg‐positive CHB patients who are from 99‐01 
study, as described before,24 in brief, received combination therapy 
with weekly doses of 100 μg PEG‐IFN (PegIntron, Schering‐Plough) 
and a daily dose of 100 mg LAM (Zeffix, GlaxoSmithKline) or mono‐
therapy with 100 μg/wk PEG‐IFN and placebo. The total duration 
of treatment was 52 weeks. All the patients were followed up for 
26 weeks post‐treatment. Patient serum samples that used for 
sCD14 measurement were collected at week 12 during PEG‐IFN 
treatment and stored at −80°C. To reduce the likelihood of early pa‐
tient dropout, the dose of PEG‐IFN was lowered to 50 μg/wk in both 
treatment groups after 32 weeks.
2.3 | Assessment of serum sCD14 levels and 
laboratory variables
Serum sCD14 was assessed by an in‐house‐developed ELISA as pre‐
viously described.25 Coating antibody was purified rat anti‐human 
sCD14 (clone 55‐3, BD Biosciences). Detection antibody was bioti‐
nylated anti‐human sCD14 (clone 3‐C39, BD Biosciences). X‐Vivo 
medium (Invitrogen) was used for sample and standard dilution. 
Recombinant sCD14 from GeneTex (GTX48216‐PRO) was dissolved 
in PBS and used for standard curve. Assay diluent, used for blocking 
and dilution of antibodies, streptavidin‐HRP and TMB solution were 
all from eBioscience/Thermo Fisher. Wash buffer was PBS + 0.05% 
Tween‐20. Reaction was stopped with 1:3 v/v of H2SO4. Optical 
density (OD) at 450 nm was measured on a Bio‐Rad imager. 
Coefficients of variability (CV) of the ELISA were determined on 4 
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reference patient samples: inter‐assay CV is 7.4%, intra‐assay CV 
is 4.8%, detection range is 100 pg/mL‐0 ng/mL. All serum samples 
were 1000 times diluted. ELISA results were multiplied by 1000 to 
calculate sCD14 concentration in patient serum samples. Laboratory 
variables including ALT, HBsAg, HBeAg, HBV DNA, HBV genotype 
were measured based on the manufacturer's instructions as previ‐
ously reported.23,24
2.4 | Statistical analysis
Data are presented as mean ± SD/SEM or median (interquartile 
range, IQR) or count (percentage) as appropriate. The Mann‐Whitney 
test, Wilcoxon signed‐rank test, t test were performed for compari‐
sons between two independent groups as appropriate. Spearman's 
rank correlations were performed to evaluate the correlation be‐
tween sCD14 with other parameters. HBV DNA, HBeAg and HBsAg 
levels were logarithmically transformed. To assess the change in 
sCD14 level, serum levels were first transformed with base 2 log to 
obtain a normal distribution and a fold change in sCD14 (FC‐sCD14) 
FC = 2^(log2 
(sCD14week 12) ‐ log2 
(sCD14week 0)) value was calculated for 
each patient and used for statistical analysis. ANOVA and Tukey's 
multiple comparison test were performed for comparisons among 
multiple groups as appropriate. Two‐sided P‐values < 0.05 were 
considered statistically significant. The diagnostic performance of 
sCD14 was analysed by calculating the receiver operating charac‐
teristic (ROC) curve and area under the ROC curve (AUC). The sen‐
sitivity, specificity, positive predictive value and negative predictive 
value were calculated at the optimal cut‐off value. These analyses 
were performed using the GraphPad Prism 5 software (GraphPad 
Prism Software, Inc).
3  | RESULTS
3.1 | Patient characteristics
A total of 169 HBV patients were included in this study, of which 
15 acute self‐limited HBV patients, 60 CHB patients who never 
received treatment from each of the four recognized clinical CHB 
phases (15 each) and 94 HBeAg+ CHB patients receiving PEG‐IFN 
treatment ± lamivudine (LAM). In addition, we included 15 age‐
matched healthy controls. Patient characteristics are presented in 
Table 1. For patients receiving PEG‐IFN treatment, 82% (n = 77) 
were male. The mean age at baseline was 34 years. 56% of patients 
were receiving PEG‐IFN with LAM (n = 53), and 44% of patients were 
receiving PEG‐IFN only. 71% of patients were Caucasian (n = 67) and 
20% Asian (n = 19). HBV genotypes A, B, C, D and other/mixed were 
present in 28% (n = 26), 11% (n = 10), 17% (n = 16), 40% (n = 38) and 
4% (n = 4) of patients, respectively.
3.2 | Acute but not chronic HBV infection or its 
disease phases associated with elevated sCD14 levels 
compared to healthy individuals
In order to characterize serum sCD14 levels in different HBV disease 
phases, sCD14 levels were first assessed in an age‐matched cohort of 
acute HBV patients, treatment‐naive CHB patients and healthy con‐
trols. Serum sCD14 levels were significantly elevated in acute self‐
limiting HBV patients (mean of 3.0 µg/mL) compared to CHB patients 
(2.4 µg/mL) or healthy control individuals (2.4 µg/mL) (Figure 1A). 
The sCD14 levels in acute HBV patients tended to positively correlate 
to serum ALT levels (Spearman r = 0.53, P = 0.05; data not shown). 
F I G U R E  1   Serum sCD14 levels in healthy controls, acute HBV patients and chronic HBV patients. A, Box and whisker plots of serum 
sCD14 levels in healthy controls (n = 15), acute HBV patients (n = 15) and chronic HBV patients (n = 60). The top and bottom of the whiskers 
represent the measured maximum and minimum values, respectively. The bottom and top of the box represent the first and third quartiles, 
respectively. Mean sCD14 is depicted as horizontal lines within the boxes and were 3.0 µg/mL for acute HBV patients, 2.4 µg/mL for healthy 
controls and 2.4 µg/mL for chronic HBV (CHB) patients. *P < 0.05, ***P < 0.001 by one‐way ANOVA and Tukey's multiple comparison test. 
B, Box and whisker plots of serum sCD14 concentration of CHB patients as in A but stratified for the four phases of CHB infection. Means 
were 2.1 µg/mL for IT (Immune tolerant; n = 15), 2.6 µg/mL for IA (immune active; n = 15), 2.4 µg/mL for IC (inactive carrier; n = 15), and 
2.3 µg/mL for E‐neg (HBeAg‐negative; n = 15). ns, not significant by one‐way ANOVA
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Next, we compared sCD14 levels among the four clinical CHB phases, 
categorized on virological, biochemical and serological parameters, 
but did not find any significant differences among these groups or be‐
tween the groups and healthy controls (Figure 1B). Furthermore, for 
these CHB patients, we did not find any correlation between sCD14 
and liver damage (by serum ALT) or fibrosis stage (data not shown).
3.3 | sCD14 levels rise upon treatment with PEG‐
IFN
The underlying mechanism of action of PEG‐IFN treatment is the 
activation of the immune system. To investigate the effect of this 
treatment on serum sCD14 levels and to assess association of 
sCD14 with clinical outcome, sCD14 levels were determined in 94 
CHB patients from a retrospective cohort.24 sCD14 concentration 
in serum was assessed pretreatment (week 0) and at 12 weeks 
upon PEG‐IFN treatment. Patients in this cohort had been treated 
with PEG‐IFN ± LAM for 52 weeks, and the response to PEG‐IFN 
treatment was assessed at 26 weeks post‐treatment (week 78) 
as reported.24 Previously, it was determined that treatment of 
PEG‐IFN with LAM did not influence response rates compared 
with PEG‐IFN only,24 and we here did not detect a difference of 
sCD14 levels between CHB patients receiving PEG‐IFN with or 
without LAM (Table 2). Therefore, sCD14 data from these groups 
were pooled for further analysis (hereafter referred to as PEG‐
IFN unless specified).
Baseline sCD14 levels did not significantly differ between 
sexes, or across HBV genotypes A‐D. Correlation between baseline 
sCD14 and baseline HBsAg level was observed (Spearman r = 0.22, 
P = 0.03; data not shown). Serum sCD14 levels were significantly el‐
evated after 12 weeks of PEG‐IFN treatment in paired patient sam‐
ples (Figure 2A). Median baseline level of sCD14 was 2.1 μg/mL (IQR 
1.8‐3.0 μg/mL), and the median level at week 12 was increased to 
3.7 μg/mL (IQR 2.8‐5.1 μg/mL) (Figure 2B). No correlation was found 
between sCD14 levels (week 0 and 12) and ALT, fibrosis (Ishak score) 
or necroinflammation. sCD14 level at week 12 was associated with 
genotype (Table 2). sCD14 levels were also associated with ethnic‐
ity; Asian patients in our cohort (n = 19) displayed significant lower 
sCD14 concentrations as compared to other ethnicities (Table 2), 
across all time points.
TA B L E  2   Subgroup analysis of the serum sCD14 in the CHB patients receiving PEG‐IFN treatment
 N
sCD14 week 0 
Median (IQR) 
μg/mL P‐value
sCD14 week 12 
Median (IQR) 
μg/mL P‐value
Fold Changea of 
CD14(w12/w0) 
Median (IQR) P‐value
Sex
Male 77 2.2 (1.8, 3.1) 0.7 3.7 (2.8, 5.1) 0.6 1.6 (1.2, 2.1) 0.6
Female 17 2.0 (1.7, 2.8)  3.9 (2.7, 5.2)  1.7 (1.4, 2.7)  
Ethnicity
Caucasian 67 2.3 (1.8, 3.3) 0.02 4.2 (3.4, 5.7) <0.0001 1.7 (1.4, 2.3) 0.004
Asian 19 1.9 (1.3, 2.3)  2.6 (2.0, 2.8)  1.4 (1.0, 1.8)  
Other 8 1.9 (1.4, 2.9)  4.6 (3.6, 5.4)  2.3 (1.5, 2.9)  
HBV genotype
A 26 2.3 (1.9, 3.1) 0.3 4.1 (3.6, 6.0) 0.02 1.8 (1.5, 2.6) 0.1
B 10 2.0 (1.3, 2.4)  2.7 (2.4, 5.0)  1.7 (1.1, 2.2)  
C 16 2.0 (1.8, 3.5)  3.0 (2.2, 3.9)  1.5 (1.1, 2.0)  
D 38 2.3 (1.8, 3.5)  3.8 (2.9, 5.5)  1.5 (1.2, 2.1)  
Other/mixed 4 1.7 (1.5, 3.6)  4.6 (2.5, 5.5)  2.0 (1.3, 2.8)  
Treatment
PEG‐IFN monotherapy 53 2.0 (1.6, 3.0) 0.1 3.6 (2.6, 5.0) 0.4 1.6 (1.3, 2.4) 0.9
PEG‐IFN + LAM therapy 41 2.4 (1.9, 3.3)  4.0 (2.9, 5.2)  1.7 (1.3, 2.0)  
Response (HBeAg seroconversion)
No 72 2.1 (1.8, 3.0) 0.8 3.7 (2.7, 4.6) 0.2 1.6 (1.3, 2.0) 0.049
Yes 22 2.0 (1.5, 3.3)  4.6 (3.2, 5.6)  2.1 (1.5, 2.7)  
Response (HBeAg loss)
No 70 2.1 (1.8, 3.0) 0.4 3.6 (2.7, 4.7) 0.1 1.5 (1.3, 2.0) 0.01
Yes 24 2.0 (1.5, 3.0)  4.5 (3.4, 5.4)  2.2 (1.5, 2.7)  
All 94 2.1 (1.8, 3.0) 3.7 (2.8, 5.1) 1.6 (1.3, 2.2)  
Note: Mann‐Whitney test was used in sex, treatment and response analysis; one‐way ANOVA was used for genotype and ethnicity analysis.
aFold change of sCD14(wk12/wk0) is calculated as described in Materials and Methods section. 
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3.4 | The change of sCD14 at week 12 of treatment 
is associated with treatment response
Next, we assessed the relation between sCD14 levels and clinical out‐
come of PEG‐IFN treatment. Response to PEG‐IFN treatment was de‐
termined at 26 weeks post‐treatment (week 78) and defined as HBeAg 
seroconversion or HBeAg loss. Overall, 22 patients (23.4%) displayed 
HBeAg seroconversion, 24 patients (25.5%) showed HBeAg loss, and 
22 patients (23.4%) exhibited both HBeAg loss and HBeAg serocon‐
version (Figure S1A). After 12 weeks of treatment, the median sCD14 
level was significantly increased for both responders and nonrespond‐
ers defined by either HBeAg seroconversion or HBeAg loss (Figure 
S1B,C). Neither pretreatment nor week 12 sCD14 levels correlated 
with PEG‐IFN treatment response regardless of how it was defined 
(Table 2). Interestingly, we found that the mean FC‐sCD14(wk12/wk0) 
was significantly higher in responders compared to nonresponders 
(FCresponder = 2.0 vs FCnonresponder = 1.6 for both HBeAg seroconversion 
and HBeAg loss) (Figure 3A‐D). Receiver operating characteristic (ROC) 
curves and area under the curve (AUC) values demonstrated that the 
FC‐sCD14(wk12/wk0) can be used to select patients at week 12 that likely 
do not benefit from further PEG‐IFN treatment (Figure 3B,D). For bet‐
ter appreciation of the predictive value of FC‐sCD14(wk12/wk0), we pro‐
vided sensitivities and specificities for three cut‐off values (FCs 1.50, 
1.76 and 2.01) for each response definition (Figure 3B,D). Importantly, 
FC‐sCD14(wk12/wk0) was not associated with sex, HBV genotypes and 
treatment, however, was influenced by ethnicity as was also observed 
for the sCD14 levels at baseline and week 12 (Table 2). Because eth‐
nicity is a cofounder for FC‐sCD14(wk12/wk0) levels, we also performed 
this operation without the Asian patients (Figure S2). When excluding 
Asian patients, the AUC was even higher (Figure S2).
Knowing FC‐sCD14wk12/wk0 is associated with HBeAg sero‐
conversion and HBeAg loss, we next studied the correlation of 
FC‐sCD14 with the change in viral parameters. For this, an FC‐sC‐
D14(wk12/wk0) cut‐off of 1.5 or 2.0 was used to divide patients into 
two groups for which we calculated on‐treatment changes in HBV 
DNA, HBeAg and ALT (Figure S3A,B). All parameters declined pro‐
foundly towards week 52 but increased again post‐treatment (week 
78). CHB patients with a high change in FC‐sCD14wk12/wk0 (>2.0) dis‐
played a significant decline in HBV DNA, HBeAg and ALT after PEG‐
IFN treatment at week 78. This was not the case when groups were 
formed using the lower FC cut‐off of 1.5 and was not at all observed 
for HBsAg. No significant correlations were found between either 
sCD14 levels (pretreatment & at week 12) or the FC‐sCD14wk12/wk0 
and changes in HBV DNA, HBeAg, HBsAg and ALT post‐treatment 
(week 78; data not shown).
3.5 | Predictive value of the change of sCD14 at 
week 12 upon PEG‐IFN treatment
For the treatment of CHB patients in European countries, the 
European Association for the Study of the Liver (EASL) guideline is 
the general reference. The 2017 EASL guideline states “In HBeAg+ 
CHB patients, HBsAg levels >20,000 IU/ml for genotype B and C, 
or no decline of HBsAg levels for genotype A and D, at 12 weeks 
of PEG‐IFN therapy are associated with a very low probability of 
subsequent HBeAg seroconversion and can be used as PEG‐IFN 
stopping rules”.26 Using this EASL stopping rule, we retrospectively 
analysed our CHB patient cohort again, but now excluding patients 
who were not HBV genotype A‐D to match the EASL guideline 
that only applies to these genotypes. We found only 36% nonre‐
sponders can be excluded at week 12 upon PEG‐IFN treatment 
(specificity 80%; accuracy: 46%, 95% CI: 0.35‐0.56), leaving 64% 
nonresponders to undergo ineffective yet invasive PEG‐IFN treat‐
ment. However, by using FC‐sCD14wk12/wk0 at a cut‐off value of 1.5, 
we reached a higher sensitivity (43%) and the same specificity (80%) 
as when applying EASL HBsAg‐based stopping rules to exclude 
nonresponders. When using an FC‐sCD14wk12/wk0 cut‐off value of 
2.0, even 76% nonresponders could be selected at week 12, with an 
F I G U R E  2   Elevated sCD14 levels in CHB patients upon treatment with PEG‐IFN. A, Serum level of sCD14 was measured at week 0 and 
at week 12 of PEG‐IFN treatment in 94 HBeAg+ CHB patients. Samples from one individual are connected by a line. B, Box and whisker 
plots of serum sCD14 for the data shown in A for better visualization of the distribution of levels. The top and bottom of the whiskers 
represent the measured maximum and minimum values, respectively. The bottom and top of the box represent the first and third quartiles, 
respectively. Medians (2.1 µg/mL at week 0, 3.7 µg/mL at week 12) are depicted within the box with the horizontal lines at indicated time 
points, n = 94. ***P < 0.0001 by Wilcoxon signed‐rank test
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accuracy of 72% to classify patients correctly (95% CI of accuracy: 
0.62‐0.81, Table 3).
Combining of both markers revealed an even higher sensitiv‐
ity (84% for FC‐sCD14wk12/wk0 = 2.0 and 61% for FC‐sCD14wk12/
wk0 = 1.5 in combination with HBsAg) when compared with using 
either HBsAg or for FC‐sCD14wk12/wk0 alone (Table S1 and Table 3). 
Thus, it may be possible to exclude even more nonresponders after 
12 weeks of treatment when using both serological markers together.
Taken all together, like HBsAg decline, the change in sCD14wk12/
wk0 may thus also serve as an effective stopping criterion and may 
even be a superior negative predictive value.
4  | DISCUSSION
This is the first study to describe the association of sCD14 levels 
with PEG‐IFN treatment response in CHB. We found that a high rise 
in serum sCD14 in CHB patients at the first 12 weeks of PEG‐IFN 
treatment is associated with an increased probability of clinical 
response defined as either HBeAg seroconversion or HBeAg loss. 
Besides this major finding, we also found serum sCD14 levels ele‐
vated in acute self‐limited HBV but not in CHB relative to healthy 
controls. In addition to the HBsAg‐based stopping rule provided in 
the 2017 EASL guideline for PEG‐IFN treatment for CHB, our results 
indicate that sCD14 may serve as an additional predictive marker 
to determine the probability of sustained response to PEG‐IFN in 
HBeAg+ CHB patients at week 12.
So far, only limited studies on sCD14 in CHB infection were 
reported. Similar to our observation, Oesterreicher et al27 found 
elevated sCD14 serum levels in acute but less in chronic viral 
hepatitis compared to healthy controls. This study, however, in‐
cluded a mixed population of acute hepatitis (HAV and HBV) and 
chronic hepatitis (HBV and HCV) patients of limited size. Steyaert 
et al28 in contrast did not find any elevation of sCD14 in acute 
HBV compared to healthy controls, while levels were higher in 
CHB patients. Similarly, also in studies by Li et al21 and Sandler et 
F I G U R E  3   The change of sCD14 
at week 12 of PEG‐IFN treatment is 
associated with clinical outcome. A, 
Individual values of FC‐sCD14wk12/
wk0 and mean of responders 
(mean ± SEM = 2.0 ± 1.1) and 
nonresponders (1.6 ± 1.0) as defined by 
HBeAg seroconversion at week 78 are 
shown. Y‐axis is displayed in log scale 
with base 2. FC‐sCD14 is calculated as 
described in Materials and Methods 
section. Statistical analysis by Mann‐
Whitney test: *P < 0.05. B, ROC curve 
and AUC selecting nonresponders 
based on the FC‐sCD14wk12/wk0 at week 
12 depicted in panel A. As examples, 
sensitivities and specificities for the 
selection of nonresponders are provided 
for three FC‐sCD14 cut‐off values. 
C, Individual values and mean of FC‐
sCD14wk12/wk0 of responders (2.0 ± 1.1) 
and nonresponders (1.6 ± 1.0) as defined 
by HBeAg loss at week 78. Y‐axis is 
displayed in log scale with base 2. 
Mann‐Whitney test on logarithmically 
transformed values. *P < 0.05. D, ROC 
curve and AUC selecting nonresponders 
using the FC‐sCD14wk12/wk0 at week 12 
depicted in panel C. Sensitivities and 
specificities for three FC‐sCD14 cut‐off 
values are provided as examples
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al,20 CHB patients were investigated and sCD14 levels were found 
to be elevated in both studies, which related to fibrosis and he‐
patic inflammation. Also, the latter study, however, was based on 
a mixed cohort containing CHB and HCV patients who were not 
analysed separately. The discrepancies among these studies and 
our own data may be caused by differences in the patient popu‐
lations, level of fibrosis and/ or the sampling moment in case of 
acute HBV infection.27
Differences in patient baseline characteristics are often a barrier 
for direct comparison of data obtained from different studies. In our 
cross‐sectional study, treatment‐naïve CHB patients were catego‐
rized into four clinical phases29 based on virological, biochemical and 
serological parameters of equal numbers of patients in each disease 
phase with a similar age group. We observed that the mean sCD14 
level in the immune active phase of CHB was slightly higher as com‐
pared to the mean sCD14 level found in healthy controls which is in 
line with the previously observed relation between hepatic inflam‐
mation and sCD14 levels.20 Possibly, previous studies reporting in‐
creased sCD14 levels in CHB included a subset of CHB patients with 
more severe liver disease,20,21 while in our cohort, ~86% treatment‐
naive CHB patients have a relative low fibrosis level (<F2 by fibro‐
scan). Furthermore, we here demonstrate that ethnicity influences 
sCD14 levels which was reported before in rheumatoid arthritis pa‐
tients30 and we previously reported the same for age,25 indicating 
that also these parameters may be a cause of discrepancy.
Why and how sCD14 is secreted remains elusive. sCD14 is 
thought to be produced by monocytes, macrophage, Kupffer cells 
and primary human hepatocytes, which can be increased upon acti‐
vation by, for example, pathogen‐associated patterns and/or pro‐in‐
flammatory cytokines. The pro‐inflammatory cytokine PEG‐IFN is a 
very potent activator of the immune system31,32 that could directly 
or indirectly enhance release of sCD14 by hepatocytes and/or my‐
eloid cells.7,8,33 In our study, we found that the elevation in sCD14 in 
responders to PEG‐IFN was significantly higher compared with those 
in nonresponders, which could therefore mean that inflammation/im‐
mune activation may be more effective and/or different in respond‐
ers. The PEG‐IFN induced increase in sCD14 fits well with the notion 
that sCD14 is a marker of immune activation in a number of acute and 
chronic inflammatory conditions, including liver inflammation.30,34 
Since microbial translocation is known to contribute to inflammation 
in viral hepatitis patients,20 the observed increased sCD14 levels 
in HBV patients might also be partly due to release of CD14 from 
Kupffer cells upon stimulation by microbial products such as LPS.5
We previously demonstrated that HBsAg can activate Kupffer 
cells.35 In addition, we showed that HBsAg‐sCD14 complexes exist 
in serum of CHB patients and that HBsAg induces dendritic cell ac‐
tivation in a CD14‐dependent manner.25 Preliminary experiments 
suggest that PEG‐IFN stimulation may trigger sCD14 release by cul‐
tured Kupffer cells especially when HBsAg is present (unpublished 
data). Whether this may explain the correlation between HBsAg lev‐
els and sCD14 levels prior PEG‐IFN treatment, as demonstrated in 
our study remains to be elucidated. However, others reported an in‐
verse correlation between plasma sCD14 and HBsAg concentrations 
in CHB patients,28 which emphasizes the need for further research 
to unravel the underlying mechanisms and the possible role and re‐
lation of sCD14 with HBsAg.
PEG‐IFN has been shown to be effective, that is, achieving im‐
munological control over HBV also after ending of treatment, only in 
a minority of CHB patients. However, the limited number of patients 
who respond together with the high costs and side effects makes it 
essential to select patients who will not benefit from this therapy 
as early as possible.36 Previously, many studies have searched for 
response predictors at baseline. HBV genotype, baseline ALT, base‐
line HBV DNA,36,37 fibrosis,38 core/precore mutations39 and IP‐10 
levels40 were all reported as pretreatment predictors of PEG‐IFN 
response. Buster et al37 constructed a baseline prediction model 
Week 12
2017 EASL guideline Fold change of sCD14 cut‐off
Based on HBsAg 
levela 2.0 1.5
Value 95% CI Value 95% CI Value 95% CI
Sensitivity (true non‐
responder rate)
36% 0.25‐0.48 76% 0.64‐0.85 43% 0.31‐0.55
Specificity (true 
responder rate)
80% 0.56‐0.94 60% 0.36‐0.81 80% 0.56‐0.94
Positive predictive 
value
86% 0.71‐0.94 87% 0.79‐0.92 88% 0.75‐0.95
Negative predictive 
value
26% 0.21‐0.32 41% 0.29‐0.55 29% 0.23‐0.35
Accuracy 46% 0.35‐0.56 72% 0.62‐0.81 51% 0.40‐0.62
Note: 90 CHB patients of genotype A‐D receiving PEG‐IFN were included in this analysis.
Responder to PEG‐IFN treatment was defined as HBeAg seroconversion at week 78.
Fold change of sCD14(wk12/wk0) is calculated as described in Materials and Methods section.
aIn HBeAg+ CHB patients (26), at week 12: HBsAg > 20 000 IU/mL for genotype B & C or no 
decline of HBsAg for genotype A & D. 
TA B L E  3   Predictive value of the 
change of sCD14 at week 12 upon PEG‐
IFN treatment
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allowing prediction of sustained response to PEG‐IFN for CHB pa‐
tients with a high likelihood of response (https ://liver‐gi.nl/hepat 
itis‐b). Yet, we did not find any relationship of sCD14 levels at week 
0 or the change of sCD14 at week 12 with these reported pretreat‐
ment predictors in our cohort.
Despite these baseline predictors of PEG‐IFN response, on‐
treatment predictors of PEG‐IFN response have also been studied. 
Monitoring HBV DNA41 levels during treatment to predict response 
has limited benefits. Serum HBeAg level during treatment had been 
reported inadequately to predict treatment response in HBeAg+ 
CHB patients.39,42 Serum HBsAg upon treatment at week 12 com‐
bined with HBV genotype has been shown to be associated with 
HBeAg seroconversion at 6 months post‐treatment,43 and this 
HBsAg‐based stopping rule is included later in 2017 EASL guide‐
lines.26 Recently, some new on‐treatment predictors like hepatitis 
B core‐related antigen (HBcrAg) and HBV RNA have been studied 
on the PEG‐IFN treatment response (review by Ref.44); however, 
further study is required to validate the clinical impact of these 
markers.
The 2017 EASL guidelines recommend to combine HBV gen‐
otype and HBsAg levels to predict the probability of subsequent 
HBeAg seroconversion and to stop the PEG‐IFN therapy at week 12 
or week 24 for HBeAg+ CHB patients.26 Our study shows that the 
response to PEG‐IFN therapy in HBeAg+ patients can also be de‐
duced from the change of serum sCD14 at week 12 with respect to 
week 0. Selecting nonresponders based on the change in sCD14 lev‐
els was even slightly more sensitive than the stopping rules defined 
in the 2017 EASL guideline. Importantly, the association of sCD14 
change with response to treatment was independent of HBV geno‐
type which makes it unique compared to other reported predictors 
so far. The value of using combinational markers of sCD14 change 
and HBsAg level for treatment response should be validated by oth‐
ers in future. These results demonstrate that sCD14 could serve as 
a valuable additional early immune marker for PEG‐IFN treatment 
response to stop ineffective treatment early on.
Although this study is the first to describe that the change of 
sCD14 might be used as an stopping rule in PEG‐IFN treatment at 
week 12, there are some limitations. First, a relatively small number 
of patients were included in our study that limited us to draw firm 
conclusions on the use of sCD14 as a biomarker in CHB treatment. 
Second, although the original study contained 2 treatment arms, 
we decided to pool the patients since LAM did not add to overall 
response rate,24 and no differences in sCD14 levels were found be‐
tween CHB patients receiving PEG‐IFN with/without LAM (Table 2). 
Third, we were not able to perform external validation on using the 
change in sCD14 as an stopping reference for PEG‐IFN treatment at 
week 12, because an additional independent data set is not available 
to us. Thus, follow‐up studies on other patient cohort are needed to 
validate the use of sCD14 to stop PEG‐IFN treatment for those who 
will not benefit. Fourth, ethnicity is a confounder in our study. Our 
data suggest that predictive value of sCD14 may be lower in patients 
with Asian ethnicity that had lower sCD14 concentrations across 
all time points. Since only a limited number of patients with Asian 
ethnicity were represented in our cohort, validation of our findings 
in an independent cohort with more Asian patients is needed.
In conclusion, serum sCD14 has the potential as a biomarker to 
select patients who are unlikely to respond to PEG‐IFN treatment 
and thus suffer unnecessarily from its severe side effects. Our data 
indicate that a high rise in serum sCD14 level upon treatment is 
associated with a successful HBV‐directed immune response. This 
finding contributes to our understanding of the immunological re‐
quirements for viral eradication and calls for further research.
CONFLIC T OF INTERE S T
The authors declare that there is no conflict of interest regarding the 
publication of this article.
AUTHORS’  CONTRIBUTIONS
YD, NM, SIB, AMW and HJ designed the study. YD, AB and NM 
performed the experiments and analyses. YD and AMW wrote the 
manuscript. SIB and AMW supervised the study. NM, HJ, RAM, SIB 
and AMW critically reviewed the manuscript.
ORCID
Yingying Dou  https://orcid.org/0000‐0001‐9263‐0007 
R E FE R E N C E S
 1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology 
of hepatitis B virus infection: new estimates of age‐specific HBsAg 
seroprevalence and endemicity. Vaccine. 2012;30(12):2212‐2219.
 2. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of 
HCC. J Hepatol. 2012;56(Suppl 1):S75‐87.
 3. Rehermann B, Bertoletti A. Immunological aspects of antiviral ther‐
apy of chronic hepatitis B virus and hepatitis C virus infections. 
Hepatology. 2015;61(2):712‐721.
 4. Marcellin P, Lau G, Bonino F, et al. Peginterferon alfa‐2a alone, lami‐
vudine alone, and the two in combination in patients with HBeAg‐
negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206‐1217.
 5. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP 
on LPS‐host cell interactions. J Endotoxin Res. 2005;11(4):225‐229.
 6. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. 
Lancet Infect Dis. 2002;2(3):171‐179.
 7. Su GL, Dorko K, Strom SC, Nussler AK, Wang SC. CD14 ex‐
pression and production by human hepatocytes. J Hepatol. 
1999;31(3):435‐442.
 8. Durieux J‐J, Vita N, Popescu O, et al. The two soluble forms of the 
lipopolysaccharide receptor, CD14: characterization and release by 
normal human monocytes. Eur J Immunol. 1994;24(9):2006‐2012.
 9. Meuleman P, Steyaert S, Libbrecht L, et al. Human hepatocytes se‐
crete soluble CD14, a process not directly influenced by HBV and 
HCV infection. Clin Chim Acta. 2006;366(1–2):156‐162.
 10. Meiler C, Muhlbauer M, Johann M, et al. Different effects of a CD14 
gene polymorphism on disease outcome in patients with alcoholic 
liver disease and chronic hepatitis C infection. World J Gastroenterol. 
2005;11(38):6031‐6037.
 11. Jirillo E, Amati L, Caradonna L, et al. Soluble (s) CD14 and plasmatic 
lipopolysaccharides (LPS) in patients with chronic hepatitis C before 
     |  1085DOU et al.
and after treatment with interferon (IFN)‐alpha. Immunopharmacol 
Immunotoxicol. 1998;20(1):1‐14.
 12. Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 
serum levels and altered CD14 expression of peripheral blood mono‐
cytes in HIV‐infected patients. Clin Exp Immunol. 1994;98(3):369‐374.
 13. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of 
monocyte‐macrophage activation markers upon anti‐CD4 treatment. 
Decreased levels of IL‐1, IL‐6, neopterin and soluble CD14 in patients 
with rheumatoid arthritis. Clin Exp Immunol. 1993;91(2):207‐213.
 14. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF‐
alpha by intravenous infusion of a chimeric monoclonal TNF‐alpha 
antibody in patients with rheumatoid arthritis. Short term cellular 
and molecular effects. J Immunol. 1996;156(4):1646‐1653.
 15. Brettschneider J, Ecker D, Bitsch A, et al. The macrophage ac‐
tivity marker sCD14 is increased in patients with multiple scle‐
rosis and upregulated by interferon beta‐1b. J Neuroimmunol. 
2002;133(1–2):193‐197.
 16. Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. 
Elevated levels of serum‐soluble CD14 in human immunodeficiency 
virus type 1 (HIV‐1) infection: correlation to disease progression 
and clinical events. Blood. 1998;92(6):2084‐2092.
 17. Fernandez‐Botran R, Joshi‐Barve S, Ghare S, et al. Systemic cyto‐
kine and interferon responsiveness Patterns in HIV and HCV mono 
and co‐infections. J Interferon Cytokine Res. 2014;34(11):885‐893.
 18. Thiebaut R, Charpentier C, Damond F, et al. Association of soluble 
CD14 and inflammatory biomarkers with HIV‐2 disease progres‐
sion. Clin Infect Dis. 2012;55(10):1417‐1425.
 19. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble 
CD14 independently predict mortality in HIV infection. J Infect Dis. 
2011;203(6):780‐790.
 20. Sandler NG, Koh C, Roque A, et al. Host response to translocated 
microbial products predicts outcomes of patients with HBV or HCV 
infection. Gastroenterology. 2011;141(4):1220–1230, 30 e1–3.
 21. Li NA, Zhu Q, Yang C, et al. Elevated serum soluble CD14 levels in 
chronic HBV infection are significantly associated with HBV‐related 
hepatocellular carcinoma. Tumour Biol. 2016;37(5):6607–6617.
 22. Medhat E, Salama H, Fouad H, et al. Serum soluble CD14 in 
Egyptian patients with chronic hepatitis C: Its relationship to dis‐
ease progression and response to treatment. J Interferon Cytokine 
Res. 2015;35(7):563–568.
 23. Vanwolleghem T, Hou J, van Oord G, et al. Re‐evaluation of hepati‐
tis B virus clinical phases by systems biology identifies unappreci‐
ated roles for the innate immune response and B cells. Hepatology. 
2015;62(1):87–100.
 24. Janssen H, van Zonneveld M, Senturk H, et al. Pegylated in‐
terferon alfa‐2b alone or in combination with lamivudine for 
HBeAg‐positive chronic hepatitis B: a randomised trial. Lancet. 
2005;365(9454):123–129.
 25. van Montfoort N, van der Aa E, van den Bosch A, et al. Hepatitis B 
virus surface antigen activates myeloid dendritic cells via a soluble 
CD14‐dependent mechanism. J Virol. 2016;90(14):6187–6199.
 26. European Association for the Study of the Liver. Electronic ad‐
dress eee, European Association for the Study of the L. EASL 2017 
Clinical Practice Guidelines on the management of hepatitis B virus 
infection. J Hepatol. 2017;67(2):370–398.
 27. Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in 
vitro production and serum levels of the soluble lipopolysaccharide 
receptor sCD14 in liver disease. J Hepatol. 1995;23(4):396–402.
 28. Steyaert S, Vanlandschoot P, Van Vlierberghe H, Diepolder H, 
Leroux‐Roels G. Soluble CD14 levels are increased and inversely 
correlated with the levels of hepatitis B surface antigen in chronic 
hepatitis B patients. J Med Virol. 2003;71(2):188–194.
 29. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infec‐
tion: what we knew in 1981 and what we know in 2005. Hepatology. 
2006;43(2 Suppl 1):S173–S181.
 30. Mikuls TR, LeVAN TD, Sayles H, et al. Soluble CD14 and 
CD14 polymorphisms in rheumatoid arthritis. J Rheumatol. 
2011;38(12):2509–2516.
 31. Heim MH, Bochud PY, George J. Host ‐ hepatitis C viral interac‐
tions: The role of genetics. J Hepatol. 2016;65(1 Suppl):S22–S32.
 32. Crosignani A, Riva A, Della BS. Analysis of peripheral blood den‐
dritic cells as a non‐invasive tool in the follow‐up of patients with 
chronic hepatitis C. World J Gastroenterol. 2016;22(4):1393–1404.
 33. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble 
CD14 is a nonspecific marker of monocyte activation. AIDS. 
2015;29(10):1263–1265.
 34. Ogawa Y, Imajo K, Yoneda M, et al. Soluble CD14 levels reflect liver 
inflammation in patients with nonalcoholic steatohepatitis. PLoS 
ONE. 2013;8(6):e65211.
 35. Boltjes A, van Montfoort N, Biesta PJ, et al. Kupffer cells inter‐
act with hepatitis B surface antigen in vivo and in vitro, leading to 
proinflammatory cytokine production and natural killer cell func‐
tion. J Infect Dis. 2015;211(8):1268–1278.
 36. Rijckborst V, Janssen HL. The role of interferon in hepatitis B ther‐
apy. Curr Hepat Rep. 2010;9(4):231–238.
 37. Buster EH, Hansen BE, Lau G, et al. Factors that predict response 
of patients with hepatitis B e antigen‐positive chronic hepatitis B to 
peginterferon‐alfa. Gastroenterology. 2009;137(6):2002–2009.
 38. Buster E, Hansen BE, Buti M, et al. Peginterferon alpha‐2b is safe 
and effective in HBeAg‐positive chronic hepatitis B patients with 
advanced fibrosis. Hepatology. 2007;46(2):388–394.
 39. Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore 
and core promoter mutants limits the probability of response to 
peginterferon in hepatitis B e antigen‐positive chronic hepatitis B. 
Hepatology. 2012;56(1):67–75.
 40. Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. 
Serum levels of interferon‐gamma‐inducible protein 10 and re‐
sponse to peginterferon therapy in HBeAg‐positive chronic hepati‐
tis B. J Hepatol. 2013;58(5):898–903.
 41. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline 
during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hep‐
atitis B: relation to treatment response. Hepatology. 2006;44(3):721–727.
 42. Sonneveld MJ, Rijckborst V, Zwang L, et al. Hepatitis B e antigen 
levels and response to peginterferon: influence of precore and basal 
core promoter mutants. Antiviral Res. 2013;97(3):312–317.
 43. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response‐guided 
peginterferon therapy in hepatitis B e antigen‐positive chronic hep‐
atitis B using serum hepatitis B surface antigen levels. Hepatology. 
2013;58(3):872–880.
 44. Höner zu Siederdissen C, Maasoumy B, Cornberg M. New viral 
biomarkers for Hepatitis B: Are we able to change practice? J Viral 
Hepat. 2018;25(11):1226–1235.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section at the end of the article.    
How to cite this article: Dou Y, van Montfoort N, van den 
Bosch A, et al. Elevated serum levels of soluble CD14 in 
HBeAg‐positive chronic HBV patients upon Peginterferon 
treatment are associated with treatment response. J Viral 
Hepat. 2019;26:1076–1085. https ://doi.org/10.1111/jvh.13127 
